



Transparency notification FMR LLC

Brussels (Belgium), 6 February 2024 – 20:00 (CET) – Regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it received a transparency notification from FMR LLC. (having its registered office at The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801, U.S.A.) on 2 February 2024.

FMR LLC., notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA increased and crossed the 5% threshold on 30 January 2024.

On 30 January 2024, FMR LLC. (taking into account the holding of its affiliates) owned 9.874.030 UCB shares with voting rights, representing 5,08% of the total number of shares issued by the company (194 505 658), versus 4.37% (8 502 358 UCB shares) in the previous notification dated 24 May 2023.

2. Content of the notification

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
FMR LLC	The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801.

- **Date on which the threshold is crossed:** 30 January 2024.
- **Threshold crossed (in %):** 5%.
- **Denominator:** 194 505 658.



- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
		# of voting rights	# of voting rights		% of voting rights
	Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities	
Holdings of voting rights					
FMR LLC	0	0		0,00%	
FIAM LLC	968.411	1.159.647		0,60%	
Fidelity Management & Research Company LLC	5.845.448	6.807.856		3,50%	
Fidelity Management Trust Company	936.274	1.103.906		0,57%	
Fidelity Institutional Asset Management Trust Company	377.585	450.603		0,23%	
FMR Investment Management (UK) Limited	119.300	134.300		0,07%	
Strategic Advisers LLC	255.340	217.719		0,11%	
Subtotal	8.502.358	9.874.030		5,08%	
TOTAL		9.874.030	0	5,08%	0,00%

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0,00%	

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	9.874.030	5,08%

- **Chain of controlled undertakings through which the holding is effectively held:**

FIAM LLC and Fidelity Institutional Asset Management Trust Company are controlled by FIAM Holdings LLC.
 FMR Investment Management (UK) Limited is controlled by Fidelity Management & Research Company LLC.
 Strategic Advisers LLC is controlled by Fidelity Advisory Holdings LLC.
 FIAM Holdings LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, Fidelity Advisory Holdings LLC are controlled by FMR LLC.
 FMR LLC is not a controlled undertaking.

- **Additional information:** The holdings attributed to the entities mentioned in heading 10 arise from holdings of various undertakings for collective investment that are managed by FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, Fidelity Management Trust Company, FMR Investment Management (UK) Limited and Strategic Advisers LLC each of which are entities that are subsidiaries of and controlled by FMR LLC. The entities mentioned in heading 10 are the discretionary investment managers and exercise the voting rights at their discretion in the absence of specific instructions.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

For further information, contact UCB:

Investor Relations

Antje Witte
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications

Laurent Schots
T+32 2 559 92 64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 700 people in nearly 40 countries, the company generated revenue of € 5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news